Trials / Unknown
UnknownNCT04077905
Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.
A Prospective Study on the Modified DEP Regimen Induction Therapy in Lymphoma Induced Hemophagocytic Lymphohistiocytosis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin together with etoposide and methylprednisolone as a induction therapy for lymphoma induced hemophagocytic lymphohistiocytosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated liposomal doxorubicin | 35mg/m² ivgtt on day 1 |
| DRUG | Etoposide | 100mg/m² ivgtt on day 1 |
| DRUG | Methylprednisolone | 2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14, |
Timeline
- Start date
- 2019-08-31
- Primary completion
- 2021-07-31
- Completion
- 2021-07-31
- First posted
- 2019-09-04
- Last updated
- 2019-09-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04077905. Inclusion in this directory is not an endorsement.